News | Stents Carotid | May 01, 2023

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system 

Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system

May 1, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first carotid artery disease patient has been treated utilizing CGuard Prime, the company’s next generation CAS stent platform. The procedure was performed by Dr. Anish Thomas of Mercy Hospital South in St. Louis, MO, as part of InspireMD’s ongoing CGuardians U.S. IDE trial. 

Marvin Slosman, chief executive officer of InspireMD, stated, “We are very pleased to have achieved this remarkable milestone – the successful first-in-human stenting procedure using CGuard Prime - as the final step in a lengthy development process as we work to advance new technology to build on our well established CGuard stent performance. I am very proud of the entire InspireMD organization for their tireless work building this platform and I would like to thank Dr. Anish Thomas and his staff for their leadership in performing these procedures. Our next generation feature set incorporated into CGuard Prime provides physicians with greater capabilities and confidence in the deployment of CGuard, our third generation MicroNet mesh protected stent. I am excited for our future as we continue to innovate and provide advanced technologies.” 

Dr. Anish Thomas, cardiologist at Mercy Hospital South, St. Louis, added, “The favorable post-procedural short- and long-term patient outcomes for carotid artery disease patients treated with CGuard EPS have been well documented across a number of rigorously designed clinical studies. With the advanced features of the CGuard Prime CAS delivery system, including its innovative handle design, and catheter and tip construction, the ease of stent trackability and deployment have been taken to the next level, which should only accelerate its uptake among interventionalists and surgeons alike. I am delighted to have successfully performed the first case with CGuard Prime, and I am pleased to play a continuing role in advancing this novel stent technology toward potential FDA approval.” 

InspireMD anticipates completing enrollment in the CGuardians U.S. IDE trial by the end of the second quarter 2023. The company will provide an additional update on this and other recent developments during its regularly scheduled Q1 2023 earnings conference call. 

For more information: www.inspiremd.com 

Related Carotid Stent Content: 
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists 
CGuard Embolic Prevention Carotid Stent Receives French Reimbursement Approval  
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial 
Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients 
GlobalData: Stenting Viable Alternative to Surgery in Carotid Artery Stenosis 
Accreditation for Cardiovascular Excellence (ACE) Selected by CMS to accredit CREST-2 Registry Clinical Sites 

 


Related Content

News | Stents Carotid

June 26, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home June 26, 2023
Home
News | Stents Carotid

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home December 13, 2022
Home
News | Stents Carotid

August 3, 2022 — Research from Ochsner Health published in the Journal of the American College of Cardiology is likely ...

Home August 03, 2022
Home
News | Stents Carotid
February 28, 2022 – InspireMD, Inc., a global developer of the CGuard Embolic Prevention Stent System (EPS) device for ...
Home February 28, 2022
Home
News | Stents Carotid

January 5, 2022 – A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for ...

Home January 05, 2022
Home
News | Stents Carotid

October 15, 2021 — The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery ...

Home October 15, 2021
Home
News | Stents Carotid

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment ...

Home November 11, 2019
Home
News | Stents Carotid

June 13, 2019 — Silk Road Medical Inc. announced the presentation of real-world data for the treatment of patients with ...

Home June 13, 2019
Home
News | Stents Carotid

July 30, 2018 — Silk Road Medical Inc. recently announced the presentation of real-world data for the treatment of ...

Home July 30, 2018
Home
News | Stents Carotid

November 18, 2016 — InspireMD Inc. announced in mid-October the online publication of positive clinical data in a new ...

Home November 18, 2016
Home
Subscribe Now